Top

Published in:

Open Access 01-03-2015 | Commentary

‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’

Author: Wolfgang H. Jost

Published in: Drugs in R&D | Issue 1/2015

Excerpt

Presently, we have a large number of botulinum neurotoxins (BoNTs) at our disposal, but in the western hemisphere these are limited almost exclusively to the botulinum toxin A preparations: Abo- (ABO), inco- (INCO), and onabotulinumtoxinA (ONA). Because these are biological preparations, they are never identical to each other, but they are, at most, similar to each other. Their efficacy has been well demonstrated in numerous studies and is undebated [1]. Since their introduction, new batches have repeatedly been made available, and the purity of ABO and ONA has essentially been improved upon. INCO is the most recent formulation and is free of complex proteins. …

Truong D, Jost WH. Therapeutical use of botulinum toxin. Parkinsonism Rel Disord. 2006;12:331–55.CrossRef

Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15. doi:10.1007/s40268-014-0077-1.

Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120:275–90.CrossRefPubMedCentralPubMed

Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox^®) and incobotulinumtoxinA (Xeomin^®) in an LD50 assay. J Neural Transm. 2012;119:13–5.CrossRefPubMed

Brown M, Nicholson G, Ardila MC, et al. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. J Neural Transm. 2013;120:291–8.CrossRefPubMed

Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol. 2009;32:28–31.CrossRefPubMed

Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949–51.CrossRefPubMed

Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–12.CrossRefPubMed

Moers-Carpi M, Dirschka T, Feller-Heppt G, et al. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. J Cosmet Laser Ther. 2012;14:296–303.CrossRefPubMed

10.

Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biol Targets Ther. 2014;8:227–41.CrossRef

11.

Brandau DT, Joshi SB, Smalter AM, et al. Stability of the clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. Mol Pharm. 2007;4:571–82.CrossRefPubMed

12.

Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN^®) in focal dystonia. Drugs. 2007;67:669–83.CrossRefPubMed

Title: ‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’
Author: Wolfgang H. Jost
Publication date: 01-03-2015
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 1/2015
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-015-0086-8

2024 ASCO Annual Meeting

Springer Medicine

‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis

Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Naïve HIV-1-Infected Patients

Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products

mTOR: A Potential Therapeutic Target in Osteoarthritis?

Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study

Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature